Literature DB >> 16987250

Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia.

Masayuki Ide1, Tetsuo Ohnishi, Miyuki Murayama, Izuru Matsumoto, Kazuo Yamada, Yoshimi Iwayama, Irina Dedova, Tomoko Toyota, Takashi Asada, Akihiko Takashima, Takeo Yoshikawa.   

Abstract

The protein kinase v-akt murine thymoma viral oncogene homolog (AKT) gene family comprises three human homologs that phosphorylate and inactivate glycogen synthase kinase 3beta (GSK3beta). Studies have reported the genetic association of AKT1 with schizophrenia. Additionally, decreased AKT1 protein expression and the reduced phosphorylation of GSK3beta were reported in this disease, leading to a new theory of attenuated AKT1-GSK3beta signaling in schizophrenia pathogenesis. We have evaluated this theory by performing both genetic and protein expression analyses. A family based association test of AKT1 did not show association with schizophrenia in Japanese subjects. The expression levels of total AKT, AKT1 and phosphorylated GSK3beta detected in the schizophrenic brains from two different brain banks also failed to support the theory. In addition, no attenuated AKT-GSK3beta signaling was observed in the lymphocytes from Japanese schizophrenics, contrasting with previous findings. Importantly, we found that the level of phosphorylated GSK3beta at Ser9 tended to be inversely correlated with postmortem intervals, and that the phosphorylation levels of AKT were inversely correlated with brain pH, issues not assessed in the previous study. These data introduce a note of caution when estimating the phosphorylation levels of GSK3beta and AKT in postmortem brains. Collectively, this study failed to support reduced signaling of the AKT-GSK3beta molecular cascade in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987250     DOI: 10.1111/j.1471-4159.2006.04033.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Regulation of glycogen synthase kinase-3 in patients with affective disorders.

Authors:  W Timothy O'Brien; Peter S Klein
Journal:  Biol Psychiatry       Date:  2007-01-15       Impact factor: 13.382

2.  AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older Caucasians.

Authors:  Jennifer A McKenzie; Sarah Witkowski; Andrew T Ludlow; Stephen M Roth; James M Hagberg
Journal:  Exp Physiol       Date:  2010-11-19       Impact factor: 2.969

3.  Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function.

Authors:  Darrick T Balu; Gregory C Carlson; Konrad Talbot; Hala Kazi; Tiffany E Hill-Smith; Rachel M Easton; Morris J Birnbaum; Irwin Lucki
Journal:  Hippocampus       Date:  2010-11-03       Impact factor: 3.899

Review 4.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.

Authors:  R R Girgis; J A Javitch; J A Lieberman
Journal:  Mol Psychiatry       Date:  2008-04-15       Impact factor: 15.992

5.  AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.

Authors:  Ruud van Winkel; Nico J M van Beveren; Claudia Simons
Journal:  Neuropsychopharmacology       Date:  2011-07-20       Impact factor: 7.853

Review 6.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

7.  AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families.

Authors:  Dawn L Thiselton; Vladimir I Vladimirov; Po-Hsiu Kuo; Joseph McClay; Brandon Wormley; Ayman Fanous; Francis A O'Neill; Dermot Walsh; Edwin J C G Van den Oord; Kenneth S Kendler; Brien P Riley
Journal:  Biol Psychiatry       Date:  2007-09-06       Impact factor: 13.382

8.  Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins.

Authors:  Olli P H Pietiläinen; Tiina Paunio; Anu Loukola; Annamari Tuulio-Henriksson; Tuula Kieseppä; Paul Thompson; Arthur W Toga; Theo G M van Erp; Karri Silventoinen; Pia Soronen; William Hennah; Joni A Turunen; Juho Wedenoja; Outi M Palo; Kaisa Silander; Jouko Lönnqvist; Jaakko Kaprio; Tyrone D Cannon; Leena Peltonen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

9.  Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice.

Authors:  Michael A Siuta; Sabrina D Robertson; Heidi Kocalis; Christine Saunders; Paul J Gresch; Vivek Khatri; Chiyo Shiota; J Philip Kennedy; Craig W Lindsley; Lynette C Daws; Daniel B Polley; Jeremy Veenstra-Vanderweele; Gregg D Stanwood; Mark A Magnuson; Kevin D Niswender; Aurelio Galli
Journal:  PLoS Biol       Date:  2010-06-08       Impact factor: 8.029

10.  Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.

Authors:  Hao-Yang Tan; Kristin K Nicodemus; Qiang Chen; Zhen Li; Jennifer K Brooke; Robyn Honea; Bhaskar S Kolachana; Richard E Straub; Andreas Meyer-Lindenberg; Yoshitasu Sei; Venkata S Mattay; Joseph H Callicott; Daniel R Weinberger
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.